Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local dexmedetomidine, ketamine, and midazolam vs bupivacaine for postoperative pain after burn debridement
IRCT20141209020258N197Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dexmedetomidine, ketamine, midazolam and bupivacaine in burn injury (4 arms), sponsored by Arak University of Medical Sciences. Primary endpoint: Postoperative pain intensity. Started Jun 2025; status: completed.
02
Drugs
dexmedetomidineketaminemidazolambupivacaine
03
Conditions
burn injury
Beyond the preview
Go deeper on IRCT20141209020258N197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N197.